- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00058968
A Study for the Treatment of Painful Diabetic Neuropathy
May 16, 2007 updated by: Eli Lilly and Company
Duloxetine Versus Placebo in the Treatment of Patients With Painful Diabetic Neuropathy
The purpose of the study is to determine if duloxetine can help patients with painful diabetic neuropathy.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The protocol will assess the efficacy and safety of duloxetine.
It will also look at how duloxetine affects quality of life.
Study Type
Interventional
Enrollment
660
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Pembroke Pines, Florida, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female outpatients at least 18 years of age.
- Patients with pain due to diabetic neuropathy in both legs.
- Females must not be pregnant or plan to become pregnant during the study.
- Stable Glycemic control.
- Average mean pain severity score of at least 4.0 as assessed by completion of a daily diary.
Exclusion Criteria:
- You are related to or work for the physician conducting the study or are employed by Eli Lilly and Company.
- You have a severe or serious medical condition that causes you to be hospitalized often; or you have had a kidney transplant or are on current dialysis.
- You have participated in a study for an investigational drug within the last 30 days.
- You have a history of major depressive disorder, generalized anxiety disorder, or alcohol or eating disorders.
- You have a past medical history or diagnosis of mania, bipolar disorder, or psychosis.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Reduction in average pain severity as measured by an 11-point Likert scale.
|
Secondary Outcome Measures
Outcome Measure |
---|
Pain severity for worst pain and night pain as measured by an 11-point Likert scale.
|
Clinical Global Impression of Severity scale to measure severity of illness at the time of assessment.
|
Patient Global Impression of Improvement scale to measure the degree of improvement at the time of assessment.
|
Brief Pain Inventory to measure the severity of pain.
|
Sensory Portion of the Short Form McGill pain questionnaire measures severity of 11 pain descriptors.
|
Hamilton Depression Rating Scale (17 item) used to assess severity of depression symptoms during the course of therapy.
|
Dynamic Allodynia measure to elicit the pain severity to a normally non-painful stimulus.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours EST), Eli Lilly and Company
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2002
Study Completion (Actual)
March 1, 2005
Study Registration Dates
First Submitted
April 15, 2003
First Submitted That Met QC Criteria
April 15, 2003
First Posted (Estimate)
April 16, 2003
Study Record Updates
Last Update Posted (Estimate)
May 17, 2007
Last Update Submitted That Met QC Criteria
May 16, 2007
Last Verified
May 1, 2007
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neurologic Manifestations
- Endocrine System Diseases
- Diabetes Complications
- Diabetes Mellitus
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Pain
- Diabetic Neuropathies
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Dopamine Agents
- Serotonin and Noradrenaline Reuptake Inhibitors
- Duloxetine Hydrochloride
Other Study ID Numbers
- 4097
- F1J-MC-HMAV
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Neuropathy, Painful
-
Helixmith Co., Ltd.CompletedDiabetic Neuropathy, Painful | Painful Diabetic NeuropathyUnited States
-
Helixmith Co., Ltd.CompletedDiabetic Neuropathy, Painful | Painful Diabetic NeuropathyUnited States
-
WinSanTor, IncCompletedPeripheral Neuropathy | Painful Diabetic Neuropathy | Diabetic Neuropathies, PainfulCanada
-
Maastricht University Medical CenterCompletedPainful Diabetic Neuropathy | Diabetic Neuropathies, Painful | Neuralgia, DiabeticNetherlands
-
University of PlymouthNot yet recruitingDiabetic Peripheral Neuropathy | Painful Diabetic Neuropathy
-
Nevro CorpRecruitingPainful Diabetic NeuropathyUnited States
-
Dartmouth-Hitchcock Medical CenterRecruitingPainful Diabetic NeuropathyUnited States
-
Duta Wacana Christian UniversityPT SOHO Global Health TbkUnknownPainful Diabetic NeuropathyIndonesia
-
Helixmith Co., Ltd.Completed
-
BioDelivery Sciences InternationalCompletedNeuropathy | Painful Diabetic Neuropathy | Diabetic NeuropathyUnited States
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States